

2023-2024

THÈSE

pour le

DIPLÔME D'ÉTAT DE DOCTEUR EN MÉDECINE

Qualification en Chirurgie maxillo-faciale et stomatologie

TREATMENT-EMERGENT CENTRAL SLEEP APNEA IN PATIENTS TREATED WITH A MANDIBULAR ADVANCEMENT DEVICE

APNEES CENTRALES DU SOMMEIL EMERGENTES SOUS TRAITEMENT PAR
ORTHESE D'AVANCEE MANDIBULAIRE

AÏSSANI Hédi

Né le 25 octobre 1996 à MARSEILLE (13), FRANCE

Sous la direction de M. le Professeur Jean-Daniel KUN-DARBOIS

Membres du jury

Monsieur le Professeur TRZEPIZUR Wojciech	Président
Monsieur le Professeur KUN-DARBOIS Jean-Daniel	Directeur
Madame le Docteur QUEIROS Chrystelle	Membre
Monsieur le Docteur GUEUTIER Alexandre	Membre

Soutenue publiquement le :
3 octobre 2024



**FACULTÉ
DE SANTÉ**
UNIVERSITÉ D'ANGERS

ENGAGEMENT DE NON PLAGIAT

Je, soussigné M. Hédi AÏSSANI
déclare être pleinement conscient que le plagiat de documents ou d'une
partie d'un document publiée sur toutes formes de support, y compris l'internet,
constitue une violation des droits d'auteur ainsi qu'une fraude caractérisée.
En conséquence, je m'engage à citer toutes les sources que j'ai utilisées
pour écrire ce rapport ou mémoire.

signé par l'étudiant le **06/08/2024**

SERMENT D'HIPPOCRATE

« Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité. Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux. Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité. J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences. Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences. Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire.

Admis dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les mœurs. Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément.

Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission. Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés.

J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité. Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré et méprisé si j'y manque ».

LISTE DES ENSEIGNANTS DE LA FACULTÉ DE SANTÉ D'ANGERS

Doyen de la Faculté : Pr Nicolas Lerolle

Vice-Doyen de la Faculté et directeur du département de pharmacie :
Pr Sébastien Faure

Directeur du département de médecine : Pr Cédric Annweiler

PROFESSEURS DES UNIVERSITÉS

ABRAHAM Pierre	PHYSIOLOGIE	Médecine
ANGOULVANT Cécile	MEDECINE GENERALE	Médecine
ANNWEILER Cédric	GERIATRIE ET BIOLOGIE DU VIEILLISSEMENT	Médecine
ASFAR Pierre	REANIMATION	Médecine
AUBE Christophe	RADIOLOGIE ET IMAGERIE MEDICALE	Médecine
AUGUSTO Jean-François	NEPHROLOGIE	Médecine
BAUFRETON Christophe	CHIRURGIE THORACIQUE ET CARDIOVASCULAIRE	Médecine
BELLANGER William	MEDECINE GENERALE	Médecine
BELONCLE François	REANIMATION	Médecine
BENOIT Jean-Pierre	PHARMACOTECHNIE	Pharmacie
BIERE Loïc	CARDIOLOGIE	Médecine
BIGOT Pierre	UROLOGIE	Médecine
BONNEAU Dominique	GENETIQUE	Médecine
BOUCHARA Jean-Philippe	PARASITOLOGIE ET MYCOLOGIE	Médecine
BOUET Pierre-Emmanuel	GYNECOLOGIE-OBSTETRIQUE	Médecine
BOURSIER Jérôme	GASTROENTEROLOGIE ; HEPATOLOGIE	Médecine
BOUVARD Béatrice	RHUMATOLOGIE	
BRIET Marie	PHARMACOLOGIE	Médecine
CALES Paul	GASTROENTEROLOGIE ; HEPATOLOGIE	Médecine
CAMPONE Mario	CANCEROLOGIE ; RADIOTHERAPIE	Médecine
CAROLI-BOSC François-Xavier	GASTROENTEROLOGIE ; HEPATOLOGIE	Médecine
CASSEREAU Julien	NEUROLOGIE	Médecine
CLERE Nicolas	PHARMACOLOGIE / PHYSIOLOGIE	Pharmacie
CONNAN Laurent	MEDECINE GENERALE	Médecine
COPIN Marie-Christine	ANATOMIE ET CYTOLOGIE PATHOLOGIQUES	Médecine
COUTANT Régis	PEDIATRIE	Médecine
CUSTAUD Marc-Antoine	PHYSIOLOGIE	Médecine
CRAUSTE-MANCIET Sylvie	PHARMACOTECHNIE HOSPITALIERE	Pharmacie
DE CASABIANCA Catherine	MEDECINE GENERALE	Médecine
DESCAMPS Philippe	GYNECOLOGIE-OBSTETRIQUE	Médecine
D'ESCATHA Alexis	MEDECINE ET SANTE AU TRAVAIL	Médecine
DINOMAS Mickaël	MEDECINE PHYSIQUE ET DE READAPTATION	Médecine

DIQUET Bertrand	PHARMACOLOGIE FONDAMENTALE ; PHARMACOLOGIE CLINIQUE ; ADDICTOLOGIE	Médecine
DUBEE Vincent	MALADIES INFECTIEUSES ET TROPICALES	Médecine
DUCANCELLE Alexandra	BACTERIOLOGIE-VIROLOGIE ; HYGIENE HOSPITALIERE	Médecine
DUVAL Olivier	CHIMIE THERAPEUTIQUE	Pharmacie
DUVERGER Philippe	PEDOPSYCHIATRIE	Médecine
EVEILLARD Mathieu	BACTERIOLOGIE-VIROLOGIE	Pharmacie
FAURE Sébastien	PHARMACOLOGIE PHYSIOLOGIE	Pharmacie
FOURNIER Henri- Dominique	ANATOMIE	Médecine
FOUQUET Olivier	CHIRURGIE THORACIQUE ET CARDIOVASCULAIRE	Médecine
FURBER Alain	CARDIOLOGIE	Médecine
GAGNADOUX Frédéric	PNEUMOLOGIE	Médecine
GOHIER Bénédicte	PSYCHIATRIE D'ADULTES	Médecine
GUARDIOLA Philippe	HEMATOLOGIE ; TRANSFUSION	Médecine
GUILET David	CHIMIE ANALYTIQUE	Pharmacie
HAMY Antoine	CHIRURGIE GENERALE	Médecine
HENNI Samir	MEDECINE VASCULAIRE	Médecine
HUNAUULT-BERGER Mathilde	HEMATOLOGIE ; TRANSFUSION	Médecine
IFRAH Norbert	HEMATOLOGIE ; TRANSFUSION	Médecine
JEANNIN Pascale	IMMUNOLOGIE	Médecine
KEMPF Marie	BACTERIOLOGIE-VIROLOGIE ; HYGIENE HOSPITALIERE	Médecine
KUN-DARBOIS Daniel	CHIRURGIE MAXILLO-FACIALE ET STOMATOLOGIE	Médecine
LACOEUILLE FRANCK	RADIOPHARMACIE	Pharmacie
LACCOURREYE Laurent	OTO-RHINO-LARYNGOLOGIE	Médecine
LAGARCE Frédéric	BIOPHARMACIE	Pharmacie
LANDREAU Anne	BOTANIQUE/ MYCOLOGIE	Pharmacie
LARCHER Gérald	BIOCHIMIE ET BIOLOGIE MOLECULAIRES	Pharmacie
LASOCKI Sigismond	ANESTHESIOLOGIE-REANIMATION	Médecine
LEBDAI Souhil	UROLOGIE	Médecine
LEGENDRE Guillaume	GYNECOLOGIE-OBSTETRIQUE	Médecine
LEGRAND Erick	RHUMATOLOGIE	Médecine
LERMITE Emilie	CHIRURGIE GENERALE	Médecine
LEROLLE Nicolas	REANIMATION	Médecine
LUNEL-FABIANI Françoise	BACTERIOLOGIE-VIROLOGIE ; HYGIENE HOSPITALIERE	Médecine
LUQUE PAZ Damien	HEMATOLOGIE BIOLOGIQUE	Médecine
MARCHAIS Véronique	BACTERIOLOGIE-VIROLOGIE	Pharmacie
MARTIN Ludovic	DERMATO-VERERELOGIE BIOLOGIE ET MEDECINE DU	Médecine
MAY-PANLOUP Pascale	DEVELOPPEMENT ET DE LA REPRODUCTION	Médecine

MENEI Philippe	NEUROCHIRURGIE	Médecine
MERCAT Alain	REANIMATION	Médecine
PAPON Nicolas	PARASITOLOGIE ET MYCOLOGIE MEDICALE	Pharmacie
PASSIRANI Catherine	CHIMIE GENERALE	Pharmacie
PELLIER Isabelle	PEDIATRIE	Médecine
PETIT Audrey	MEDECINE ET SANTE AU TRAVAIL	Médecine
PICQUET Jean	CHIRURGIE VASCULAIRE ; MEDECINE VASCULAIRE	Médecine
PODEVIN Guillaume	CHIRURGIE INFANTILE	Médecine
PROCACCIO Vincent	GENETIQUE	Médecine
PRUNIER Delphine	BIOCHIMIE ET BIOLOGIE MOLECULAIRE	Médecine
PRUNIER Fabrice	CARDIOLOGIE	Médecine
RAMOND-ROQUIN Aline	MEDECINE GENERALE	Médecine
REYNIER Pascal	BIOCHIMIE ET BIOLOGIE MOLECULAIRE	Médecine
RICHOMME Pascal	PHARMACOGNOSIE	Pharmacie
RINEAU Emmanuel	ANESTHESIOLOGIE REANIMATION	Médecine
RIOU Jérémie	BIOSTATISTIQUES	Pharmacie
RODIEN Patrice	ENDOCRINOLOGIE, DIABETE ET MALADIES METABOLIQUES	Médecine
ROQUELAURE Yves	MEDECINE ET SANTE AU TRAVAIL	Médecine
ROUGE-MAILLART Clotilde	MEDECINE LEGALE ET DROIT DE LA SANTE	Médecine
ROUSSEAU Audrey	ANATOMIE ET CYTOLOGIE PATHOLOGIQUES	Médecine
ROUSSEAU Pascal	CHIRURGIE PLASTIQUE, RECONSTRUCTRICE ET ESTHETIQUE	Médecine
ROUSSELET Marie-Christine	ANATOMIE ET CYTOLOGIE PATHOLOGIQUES	Médecine
ROY Pierre-Marie	MEDECINE D'URGENCE	Médecine
SAULNIER Patrick	BIOPHYSIQUE ET BIOSTATISTIQUES	Pharmacie
SERAPHIN Denis	CHIMIE ORGANIQUE	Pharmacie
SCHMIDT Aline	HEMATOLOGIE ; TRANSFUSION	Médecine
TESSIER-CAZENEUVE Christine	MEDECINE GENERALE	Médecine
TRZEPIZUR Wojciech	PNEUMOLOGIE	Médecine
UGO Valérie	HEMATOLOGIE ; TRANSFUSION	Médecine
URBAN Thierry	PNEUMOLOGIE	Médecine
VAN BOGAERT Patrick	PEDIATRIE	Médecine
VENARA Aurélien	CHIRURGIE VISCERALE ET DIGESTIVE	Médecine
VENIER-JULIENNE Marie-Claire	PHARMACOTECHNIE	Pharmacie
VERNY Christophe	NEUROLOGIE	Médecine
WILLOTEAUX Serge	RADIOLOGIE ET IMAGERIE MEDICALE	Médecine

MAÎTRES DE CONFÉRENCES

AMMI Myriam	CHIRURGIE THORACIQUE ET CARDIOVASCULAIRE	Médecine
BAGLIN Isabelle	CHIMIE THERAPEUTIQUE	Pharmacie

BASTIAT Guillaume	BIOPHYSIQUE ET BIOSTATISTIQUES	Pharmacie
BEAUVILLAIN Céline	IMMUNOLOGIE	Médecine
BEGUE Cyril	MEDECINE GENERALE	Médecine
BELIZNA Cristina	MEDECINE INTERNE	Médecine
BENOIT Jacqueline	PHARMACOLOGIE	Pharmacie
BESSAGUET Flavien	PHYSIOLOGIE PHARMACOLOGIE	Pharmacie
BERNARD Florian	ANATOMIE ; discipline hospit : NEUROCHIRURGIE	Médecine
BLANCHET Odile	HEMATOLOGIE ; TRANSFUSION	Médecine
BOISARD Séverine	CHIMIE ANALYTIQUE	Pharmacie
BRIET Claire	ENDOCRINOLOGIE, DIABETE ET MALADIES METABOLIQUES	Médecine
BRIS Céline	BIOCHIMIE ET BIOLOGIE MOLECULAIRE	Pharmacie
CANIVET Clémence	GASTROENTEROLOGIE-HEPATOLOGIE	Médecine
CAPITAIN Olivier	CANCEROLOGIE ; RADIOTHERAPIE	Médecine
CHAO DE LA BARCA Juan-Manuel	BIOCHIMIE ET BIOLOGIE MOLECULAIRE	Médecine
CHEVALIER Sylvie	BIOLOGIE CELLULAIRE	Médecine
CHOPIN Matthieu	MEDECINE GENERALE	Médecine
CODRON Philippe	NEUROLOGIE	Médecine
COLIN Estelle	GENETIQUE	Médecine
DEMAS Josselin	SCIENCES DE LA READAPTATION	Médecine
DERBRE Séverine	PHARMACOGNOSIE	Pharmacie
DESHAYES Caroline	BACTERIOLOGIE VIROLOGIE	Pharmacie
DOUILLET Delphine	MEDECINE D'URGENCE	Médecine
FERRE Marc	BIOLOGIE MOLECULAIRE	Médecine
FORTRAT Jacques-Olivier	PHYSIOLOGIE	Médecine
GHALI Maria	MEDECINE GENERALE	Médecine
GUELFF Jessica	MEDECINE GENERALE	Médecine
HAMEL Jean-François	BIOSTATISTIQUES, INFORMATIQUE MEDICALE	Médicale
HELESBEUX Jean-Jacques	CHIMIE ORGANIQUE	Pharmacie
HERIVAUX Anaïs	BIOTECHNOLOGIE	Pharmacie
HINDRE François	BIOPHYSIQUE	Médecine
JOUSSET-THULLIER Nathalie	MEDECINE LEGALE ET DROIT DE LA SANTE	Médecine
JUDALET-ILLAND Ghislaine	MEDECINE GENERALE	Médecine
KHIATI Salim	BIOCHIMIE ET BIOLOGIE MOLECULAIRE	Médecine
LEGEAY Samuel	PHARMACOCINETIQUE	Pharmacie
LEMEE Jean-Michel	NEUROCHIRURGIE	Médecine
LE RAY-RICHOMME Anne-Marie	PHARMACOGNOSIE	Pharmacie
LEPELTIER Elise	CHIMIE GENERALE	Pharmacie
LETOURNEL Franck	BIOLOGIE CELLULAIRE	Médecine
LIBOUBAN Hélène	HISTOLOGIE	Médecine
MABILLEAU Guillaume	HISTOLOGIE, EMBRYOLOGIE ET CYTOGENETIQUE	Médecine
MALLET Sabine	CHIMIE ANALYTIQUE	Pharmacie
MAROT Agnès	PARASITOLOGIE ET MYCOLOGIE MEDICALE	Pharmacie
MESLIER Nicole	PHYSIOLOGIE	Médecine

MIOT Charline	IMMUNOLOGIE	Médecine
MOUILLIE Jean-Marc	PHILOSOPHIE	Médecine
NAIL BILLAUD Sandrine	IMMUNOLOGIE	Pharmacie
PAILHORIES Hélène	BACTERIOLOGIE-VIROLOGIE	Médecine
PAPON Xavier	ANATOMIE	Médecine
PASCO-PAPON Anne	RADIOLOGIE ET IMAGERIE MEDICALE	Médecine
PECH Brigitte	PHARMACOTECHNIE	Pharmacie
PENCHAUD Anne-Laurence	SOCIOLOGIE	Médecine
PIHET Marc	PARASITOLOGIE ET MYCOLOGIE	Médecine
POIROUX Laurent	SCIENCES INFIRMIERES	Médecine
PY Thibaut	MEDECINE GENERALE	Médecine
RIOU Jérémie	BIOSTATISTIQUES	Pharmacie
RIQUIN Elise	PEDOPSYCHIATRIE ; ADDICTOLOGIE	Médecine
RONY Louis	CHIRURGIE ORTHOPEDIQUE ET TRAUMATOLOGIQUE	Médecine
ROGER Emilie	PHARMACOTECHNIE	Pharmacie
SAVARY Camille	PHARMACOLOGIE-TOXICOLOGIE	Pharmacie
SCHMITT Françoise	CHIRURGIE INFANTILE	Médecine
SCHINKOWITZ Andréas	PHARMACOGNOSIE	Pharmacie
SPIESSER-ROBELET Laurence	PHARMACIE CLINIQUE ET EDUCATION THERAPEUTIQUE	Pharmacie
TEXIER-LEGENDRE Gaëlle	MEDECINE GENERALE	Médecine
VIAULT Guillaume	CHIMIE ORGANIQUE	Pharmacie

AUTRES ENSEIGNANTS

PRCE		
AUTRET Erwan	ANGLAIS	Santé
BARBEROUSSE Michel	INFORMATIQUE	Santé
COYNE Ashley-Rose	ANGLAIS	Santé
O'SULLIVAN Kayleigh	ANGLAIS	Santé
RIVEAU Hélène	ANGLAIS	
PAST/MAST		
BEAUVAIS Vincent	OFFICINE	Pharmacie
BRAUD Cathie	OFFICINE	Pharmacie
DILÉ Nathalie	OFFICINE	Pharmacie
GUILLET Anne-Françoise	PHARMACIE DEUST PREPARATEUR	Pharmacie
MOAL Frédéric	PHARMACIE CLINIQUE	Pharmacie
CHAMPAGNE Romain	MEDECINE PHYSIQUE ET READAPTATION	Médecine
GUITTON Christophe	MEDECINE INTENSIVE-REANIMATION	Médecine
KAASSIS Mehdi	GASTRO-ENTEROLOGIE	Médecine
LAVIGNE Christian	MEDECINE INTERNE	Médecine
PICCOLI Giorgia	NEPHROLOGIE	Médecine

POMMIER Pascal	CANCEROLOGIE-RADIOTHERAPIE	Médecine
SAVARY Dominique	MEDECINE D'URGENCE	Médecine
PLP		
CHIKH Yamina	ECONOMIE-GESTION	Médecine

REMERCIEMENTS

A Monsieur le Professeur Jean-Daniel Kun-Darbois,
A qui j'exprime ma reconnaissance pour son enseignement bienveillant et la direction efficace et attentive de ce travail de thèse. Je te remercie pour le soutien que tu m'apportes, les nombreuses compétences chirurgicales que j'ai acquises à tes côtés et la confiance que tu m'accordes depuis maintenant plusieurs années.

A Monsieur le Professeur Wojciech Trzepizur,
Votre soutien et votre implication ont été déterminants dans la production de ces travaux, de même que votre patience et vos précieuses relectures.

A Monsieur le Docteur Alexandre Gueutier,
Dont l'exigence et la polyvalence m'inspirent depuis maintenant 4 ans. J'ai énormément appris à tes côtés et j'espère continuer à bénéficier de tes précieux conseils pendant encore longtemps.

A Madame le Docteur Chrystelle Queiros,
Ton regard bienveillant, ta confiance et ton exigence font de ces 3 mois passés à tes côtés un moment clé de mon internat. Je te remercie chaleureusement pour tout ce que tu m'as appris, et pour avoir accepté de faire partie de ce jury.

A mes parents,
Dont le soutien indéfectible a contribué à faire de moi l'homme que je suis devenu.

A Sofiane, Julia et Jade,
Qui ont subi les sautes d'humeur de leur grand-frère sans jamais l'abandonner.

A mes grands-parents,
Qui ne sont malheureusement plus tous présents, mais seraient fiers de voir ce que je suis devenu.

A Léa,
Qui m'apporte tout son soutien et sa bonne humeur chaque jour, et sans qui le quotidien serait bien triste. Je te remercie pour ces 3 années passées à tes côtés et j'espère qu'elles ne sont qu'un début.

A mes amis Marseillais, Angevins, Tourangeaux,
Les moments passés à vos côtés sont inoubliables et j'espère qu'ils seront encore nombreux.

A mes co-internes, présents et passés,
J'ai appris et surtout beaucoup ri aux côtés de chacun de vous.

A l'équipe de Chirurgie Maxillo-Faciale du CHU d'Angers,
Infirmières, aides-soignantes, secrétaires, qui m'accompagnent et parfois me subissent depuis maintenant plusieurs années. Je vous remercie pour votre aide indéfectible et votre gentillesse.

Liste des abréviations

[illegible]

PLAN

ABSTRACT

1. INTRODUCTION

2. MATERIALS AND METHODS

2.1 Study population and design

2.2 MAD treatment

2.3 Sleep recordings

2.4 Subjective clinical outcomes

2.5 TECSA definitions

2.6 Statistical analysis

3. RESULTS

3.1 Baseline characteristics of the study population

3.2 Comparisons between non-TECSA and TECSA patients

3.3 Clinical outcomes evolution under MAD therapy

DISCUSSION

CONCLUSIONS

REFERENCES

LEGENDS OF FIGURES

TABLES

TABLE DES MATIERES

Treatment-emergent central sleep apnea in patients treated with a mandibular advancement device

Hédi Aïssani^a, Jean-Daniel Kün-Darbois ^{a,b,c}, Clémence Moreau^d, Frédéric Gagnadoux^{b,c}, Wojciech Trzepizur^{b,c}
on behalf of the IRSR Pays de la Loire Sleep Cohort Study Group

^a CHU Angers, Department of Maxillo-facial surgery, F-49933 Angers, France

^b CHU Angers, Department of Respiratory and Sleep Medicine, F-49933 Angers, France

^c Univ Angers, Faculty of Medicine, F-49000 Angers, France

^d CHU Angers, Delegation for Clinical Research and Innovation, F-49933 Angers, France

ABSTRACT

Objectives: Treatment-emergent central sleep apnea (TECSA) is well established in continuous positive airway pressure therapy but was barely studied in mandibular advancement device (MAD) treatment. This study aims to evaluate the prevalence of TECSA in patients treated with a MAD and to determine its risk factors and clinical relevance.

Materials and methods: A total of 139 patients from the IRSR Pays de la Loire Sleep Cohort suffering from snores or obstructive sleep apnea syndrome (OSAS) and treated with a custom-made titratable MAD were included. Baseline and follow-up sleep recordings enabled identification of TECSA patients. Comparative analyses were carried out between TECSA and non-TECSA groups to identify potential risk factors. Clinical relevance of TECSA in both groups was assessed through baseline and follow-up Pichot's self-assessment questionnaire for depressive symptoms (QD2A), 36-item short form survey (SF-36) and Epworth Sleepiness Scale (ESS) scores.

Results: According to the definition selected, a prevalence between 0% and 5.04% was found for TECSA in the present study. No statistical differences were found in terms of treatment characteristics, sleep architecture, demographic data or comorbid conditions, although there was a trend towards a higher prevalence of arterial hypertension in TECSA-1 than in non-TECSA group (42.9% vs 25.4% respectively, $p=0.379$). Baseline ESS showed a trend towards a higher score in TECSA-1 patients compared to non-TECSA patients (13/24 vs 10/24 respectively, $p=0.074$), with a high proportion of TECSA-1 patients suffering from excessive daytime sleepiness before initiation of treatment (85.7%, vs 52.4% in non-TECSA patients, $p=0.124$). No statistical differences were found regarding delta Pichot's QD2A and ESS scores between baseline and follow-up although there was a trend towards higher ESS scores at

follow-up in TECSA-1 group compared to non-TECSA patients. Median delta SF-36 score for the General health scale was significantly lower in TECSA-1 and there was a trend towards lower scores for Mental health category in TECSA-1 patients.

Conclusions: TECSA is a rare phenomenon that can occur in patients treated with a MAD for an OSAS. Clinical, polysomnographic and treatment-related risk factors have yet to be reassessed in larger cohorts. These findings suggest probably poorer subjective clinical outcomes in terms of sleepiness and quality of life in patients with MAD-related TECSA.

1. INTRODUCTION

Mandibular advancement devices (MAD) have emerged as the principal alternative to continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnea syndrome (OSAS). According to French clinical guidelines, MAD therapy is recommended as an appropriate first-line treatment option for snoring and mild to moderate OSAS in patients without severe cardiovascular comorbidity or as a second line option in patients intolerant to CPAP. Despite a lower impact of MAD on decreasing the apnea-hypopnea index (AHI), both treatments have been shown to have a similar impact on clinical outcomes, including sleepiness, and cardiovascular outcomes [1–5].

According to the International Classification of Sleep Disorders-Third Edition (ICSD-3), Treatment-Emergent Central Sleep Apnea (TECSA) is characterized by persistence or emergence of central sleep apneas on exposure to CPAP devices while obstructive events have resolved [6]. TECSA is a well-known phenomenon in patients treated with CPAP, with a prevalence ranging from 5.0% to 20.3% [7]. TECSA's natural course remains mostly unknown and its potential clinical impact is still controversial [8]. TECSA appears to resolve spontaneously with time in most cases. It may also persist leading to a higher risk of therapy discontinuation [9]. TECSA may also occur with alternative OSAS treatments, such as maxillo-mandibular advancement, upper airway surgery or tracheostomy [10]. The prevalence of TECSA in patients treated with a MAD has been assessed to date in only one study and ranged between 3.1% and 7.8% depending on TECSA definition [11].

The main objective of the study was to assess the prevalence of TECSA in a large prospective cohort of snoring and OSAS patients treated with a MAD. The secondary objectives were to identify risk factors for the occurrence of TECSA and to assess the impact of TECSA on treatment symptomatic efficacy and adherence.

2. MATERIALS AND METHODS

2.1 Study population and design

The study was performed on the *Institut de Recherche en Santé Respiratoire des Pays de la Loire [IRSR] Pays de la Loire cohort study group*. Consecutive patients treated in Angers University Hospital for OSAS or snores with a MAD, between January 2011 and October 2017 with available pre-treatment and follow-up sleep-recordings data were included in the study. All participants gave an informed consent for their participation in the study. This study was approved by the University of Angers ethics committee (Comité d’Ethique du Centre Hospitalier Universitaire d’Angers, No.2007/17 ; Comité Consultatif sur le Traitement de l’Information en matière de Recherche dans le domaine de la Santé, No 07.207 bis).

2.2 MAD treatment

Four different types of titratable bi-bloc MAD with proven efficacy in treating OSAS and snores were used in the present study. Two of them were custom-made MAD: AMO® device and SomnoDent® device (SomnoMed, Ancenis, France) [12,13]. The third one was a customizable, thermoplastic MAD: BluePro® device (BlueSom, Paris, France) [14]. The last one was a custom-made computer-aided design/computer-aided manufacturing (CAD/CAM) bi-bloc MAD: Narval CC® (ResMed, Lyon, France) [15].

All patients were fitted with the chosen device by a qualified oral and maxillo-facial surgeon or a dentist. Patients underwent MAD titration following a standardized protocol: once fitted with the MAD at 70% of maximal jaw active propulsion, patients underwent an acclimatization period during which the mandible was incrementally advanced by 1-mm steps every 1 or 2 weeks until symptom relief or the maximum comfortable limit of advancement was achieved [14]. The degree of mandibular propulsion was expressed in millimeters and in percentage of

the patient's maximal jaw active propulsion. Adherence to treatment was assessed through two criteria: the reported number of nights per week and number of hours per night MAD was used.

2.3 Sleep recordings

At baseline and after MAD titration, patients underwent polysomnography or type-III overnight respiratory recordings (CID 102 LX, Cidelec, Sainte-Gemmes sur Loire, France). Respiratory events were scored manually using recommended criteria [16]. Respiratory events were classified as obstructive or central, giving respectively the obstructive apnea index (OAI) and obstructive apnea-hypopnea index (OAHI) and the central apnea index (CAI) and central apnea-hypopnea index (CAHI). 3% Oxygen desaturation index (3% ODI) was defined as the average number of desaturations $\geq 3\%$ lasting at least 10 seconds per hour. Snoring index was defined as the number of snoring events per hour. Percentage of nighttime spent with oxygen saturation $< 90\%$ (Tsat 90%) was extracted from sleep recordings.

For patients who underwent overnight polysomnography, specific data were extracted: total sleep time (TST), time spent in rapid-eye movement (REM) and N3 sleep stages.

2.4 Subjective clinical outcomes

Subjective daytime sleepiness was assessed by the Epworth Sleepiness Scale (ESS). An ESS score $> 10/24$ defined an excessive daytime sleepiness (EDS) [17]. Depression symptoms were assessed using the Pichot's QD2A score and depressive syndrome was retained for a score $\geq 7/13$ [18,19]. 36-Item short form survey (SF-36) was used to measure patient's quality of life [2,20].

2.5 TECSA definitions

To facilitate comparison with existing literature the prevalence of TECSA was calculated according to 3 definitions [11]. TECSA-1 was defined as a follow-up CAHI $\geq$ 5/h with predominant central sleep apnea (CSA) (central apneas >50% of apnea index); TECSA-2 included, amongst patients meeting the TECSA-1 criteria, those who presented a decrease of >50% in OAHI (treatment effectiveness); TECSA-3 included patients meeting TECSA-2 criteria with only new emergent CSA, i.e. those with a baseline CAHI<5/h. According to the ICSD-3 definition of TECSA, CSA must not be attributable to another diagnosis such as drug-induced CSA or Cheyne-Stoke Breathing associated with congestive heart failure [6].

2.6 Statistical analysis

All statistical analysis were performed using the R software (version 4.0.5). Descriptive statistics were presented as numbers and percentages for qualitative variables, and as medians with 1st and 3rd quartiles for quantitative variables. For comparisons between groups, Fisher's exact test and Mann-Whitney test were used for qualitative and quantitative variables, respectively. In order to visualize differences between non-TECSA and TECSA-1 patients, adapted graphical solutions were used to represent the evolution of ESS scores over time, as well as the distribution of the differences in ESS between inclusion and the follow-up visit. A p -value<0.05 was considered statistically significant.

3. RESULTS

3.1 Baseline characteristics of the study population

A total of 139 patients were included in the analysis. The study population consisted of predominantly male (74.1%) and overweight patients (BMI 26.1 [24.5; 28.7] kg/m²). The prevalence of cardiovascular, metabolic and respiratory comorbidities was low (26.3% and 0.78% for arterial hypertension and cardiac arrhythmia respectively, 3.76% for diabetes and 5.34% for chronic obstructive pulmonary disease) (*Table I*).

A total of 93 patients underwent type III overnight polysomnography (66.90%) and 46 patients underwent overnight respiratory recording (33.09%) at baseline. Median AHI in the study population was 30.0 [17.0; 35.0] events/hour at baseline, among which 52.5% of patients presented with severe, 28.8% with moderate and 15.1% with mild OSAS (*Table II*). Median ESS score in the study population was 10 [6.0; 13.0]/24, with 54.1% of patients suffering from EDS (*Table III*). The most frequently used MAD models in the population study were the customizable thermoplastic BluePro® (47.5%) and the titratable custom-made AMO® device (43.9%). SomnoDent® device and Narval CC® were rarely used (7.91% and 0.72% respectively). Median effective MAD propulsion in the study population was of 7.0 [5.0; 8.0] millimeters and 70 [58; 80] % of the maximal jaw active propulsion (*Table IV*).

3.2 Comparisons between non-TECSA and TECSA patients

A total of 7 patients met the diagnostic criteria of TECSA-1, leading to a prevalence of 5.04% (95% CI 2.0-10.1%). Only 2 patients met the diagnostic criteria of TECSA-2, resulting in a prevalence of 1.44% (95% CI 0.2-5.1%). No patient met the diagnostic criteria of TECSA-3 in the study population. In consequence, analyses were carried out on the TECSA-1 group, which is the largest in our population and refers to the broadest definition of TECSA.

There were no statistical differences between non-TECSA and TECSA-1 groups in terms of general characteristics or comorbidities. However, the prevalence of arterial hypertension in TECSA-1 group was almost twice as high as in non-TECSA group (42.9% vs 25.4% respectively, $p=0.379$) (*Table I*).

We did not find any statistical differences between both groups regarding baseline sleepiness (ESS), quality of life (SF-36) and depressive symptoms (QD2A). However, a trend to higher baseline ESS scores was observed in TECSA-1 patients compared to non-TECSA patients (13/24 vs 10/24 respectively, $p=0.074$), with a high proportion of TECSA-1 patients suffering from EDS (85.7%, vs 52.4% in non-TECSA patients, $p=0.124$) (*Table III*).

No significant differences were found between non-TECSA and TECSA-1 groups in terms of OSAS severity, except for CAHI which is as expected significantly higher in TECSA-1 group (2.96 [1.49; 5.86] events/hour, vs 0.46 [0.12; 1.31] events/hour in non-TECSA group, $p=0.006$). Sleep architecture was comparable between both groups for patients who underwent a baseline polysomnography (*Table II*).

Good adherence to MAD therapy was achieved in the study population with a median use of 7.0 [6.0; 7.0] nights per week and 7.0 [6.0; 7.0] hours per night with no significant differences between both groups. No statistical differences were found in terms of frequency of use between different MAD models in both groups, neither regarding the treatment characteristics. The median time interval between MAD treatment initiation and follow-up overnight respiratory recording was 10 [6; 17] months (*Table IV*).

Table I. Baseline demographics and comorbidities of the study population.

Variables	Missing data	All n=139	Non-TECSA n=132	TECSA-1 n=7	<i>p</i>
General characteristics					
Age (years)	-	51.5 [44.8; 59.3]	51.7 [44.7; 59.5]	51.3 [50.0; 55.7]	0.904
Male sex	-	103 (74.1%)	98 (74.2%)	5 (71.4%)	1.000
BMI (kg/m ²)	-	26.1 [24.5; 28.7]	26.1 [24.4; 28.5]	27.5 [26.3; 30.9]	0.118
Comorbidities					
Arterial hypertension	6	35 (26.3%)	32 (25.4%)	3 (42.9%)	0.379
Cardiac arrhythmia	10	1 (0.78%)	1 (0.82%)	0 (0.00%)	1.000
Diabetes	6	5 (3.76%)	5 (3.97%)	0 (0.00%)	1.000
COPD	8	7 (5.34%)	7 (5.65%)	0 (0.00%)	1.000
Current smoking	3	32 (23.5%)	32 (24.8%)	0 (0.00%)	0.199

Data are expressed as median [IQR] for quantitative variables and as numbers and percentages for qualitative variables. The *p*-value corresponds to that obtained using comparison tests (Exact Fisher for qualitative variables, and Mann-Whitney for quantitative variables) between non-TECSA and TECSA-1 patients.

TECSA: treatment-emergent central sleep apnea; BMI: body mass Index; COPD: chronic obstructive pulmonary disease.

Table II. Baseline sleep recordings data of the study population.

Variables	Missing data	All n=139	Non-TECSA n=132	TECSA-1 n=7	<i>p</i>
OSAS severity					
Snores (events/hour)	-	205 [83.5; 341]	206 [84.8; 353]	186 [33.0; 240]	0.219
AI (events/hour)	-	3.21 [0.94; 9.16]	3.21 [0.94; 8.89]	2.40 [1.61; 13.4]	0.593
AHI (events/hour)	-	30.0 [17.0; 35.0]	30.0 [16.8; 35.0]	30.0 [26.5; 32.0]	0.636
OSAS subtypes	-				0.820
AHI<5		5 (3.60%)	5 (3.79%)	0 (0.00%)	
5≤AHI<15		21 (15.1%)	20 (15.2%)	1 (14.3%)	
15≤AHI<30		40 (28.8%)	39 (29.5%)	1 (14.3%)	
AHI≥30		73 (52.5%)	68 (51.5%)	5 (71.4%)	
OAI (events/hour)	-	2.24 [0.47; 7.91]	2.22 [0.50; 7.91]	2.28 [0.42; 7.88]	0.958
OAHI (events/hour)	-	27.0 [14.9; 32.9]	27.0 [15.0; 33.2]	26.2 [17.6; 28.5]	0.600
CAI (events/hour)	-	0.28 [0.00; 0.96]	0.27 [0.00; 0.94]	0.77 [0.37; 3.36]	0.065
CAHI (events/hour)	-	0.50 [0.12; 1.46]	0.46 [0.12; 1.31]	2.96 [1.49; 5.86]	0.006
3% ODI (events/hour)	-	17.0 [10.0; 29.0]	16.0 [10.0; 29.2]	21.0 [16.5; 28.0]	0.418
Tsat 90% (%/TST)	-	0.00 [0.00; 3.50]	0.00 [0.00; 3.00]	2.00 [0.50; 4.50]	0.229
Specific polysomnography data					
TST (minutes)	46	443 [401; 483]	442 [401; 483]	471 [448; 486]	0.421
REM (%/TST)	46	21.8 [16.8; 24.9]	21.7 [16.7; 24.9]	23.3 [22.5; 24.8]	0.447
N3 (%/TST)	46	20.5 [16.3; 25.2]	20.6 [16.3; 25.2]	19.6 [16.5; 22.9]	0.769

Data are expressed as median [IQR] for quantitative variables, and as numbers and percentages for qualitative variables. The *p*-value corresponds to that obtained using comparison tests (Exact Fisher for qualitative variables, and Mann-Whitney for quantitative variables) between non-TECSA and TECSA-1 patients.

TECSA: treatment-emergent central sleep apnea; A(H)I: apnea (-hypopnea) index; OA(H)I: obstructive apnea (-hypopnea) index; CA(H)I: central apnea (-hypopnea) index; 3% ODI: 3% oxygen desaturation index; Tsat 90%: percentage of nighttime spent with oxygen saturation <90%; TST: total sleep time; REM: rapid-eye movement sleep; N3: N3 sleep stage.

Table III. Subjective clinical outcomes' scores for the study population at baseline.

Variables	Missing data	All n=139	Non-TECSA n=132	TECSA-1 n=7	<i>p</i>
ESS (/24)	6	10.0 [6.00; 13.0]	10.0 [6.00; 13.0]	13.0 [10.0; 17.5]	0.074
EDS (ESS $\geq$ 10/24)	6	72 (54.1%)	66 (52.4%)	6 (85.7%)	0.124
SF-36					
Physical functioning	24	95.0 [90.0; 95.0]	95.0 [90.0; 95.0]	90.0 [90.0; 97.5]	0.836
Role physical	8	100 [75.0; 100]	100 [75.0; 100]	75.0 [37.5; 100]	0.186
Role emotional	6	100 [66.7; 100]	100 [66.7; 100]	66.7 [66.7; 100]	0.311
Vitality	6	45.0 [35.0; 55.0]	45.0 [35.0; 55.0]	45.0 [30.0; 55.0]	0.727
Mental health	9	68.0 [56.0; 76.0]	68.0 [56.0; 76.0]	72.0 [56.0; 78.0]	0.926
Social functioning	5	75.0 [62.5; 100]	75.0 [62.5; 100]	75.0 [62.5; 81.2]	0.661
Bodily pain	5	70.0 [57.5; 80.0]	70.0 [57.5; 80.0]	80.0 [62.5; 80.0]	0.793
General health	6	65.0 [55.0; 80.0]	65.0 [51.2; 78.8]	65.0 [57.5; 80.0]	0.915
QD2A (Pichot's score)	11	1.50 [0.00; 4.00]	1.00 [0.00; 4.00]	2.00 [1.50; 5.50]	0.367

Data are expressed as median [IQR] for quantitative variables, and as numbers and percentages for qualitative variables. The *p*-value corresponds to that obtained using comparison tests (Exact Fisher for qualitative variables, and Mann-Whitney for quantitative variables) between non-TECSA and TECSA-1 patients.

TECSA: treatment-emergent central sleep apnea; ESS: Epworth Sleepiness Scale; EDS: excessive daytime sleepiness; SF-36: 36-Item Short Form Survey; QD2A: self-assessment questionnaire for depressive symptoms.

Table IV. Treatment characteristics of the study population.

Variables	Missing data	All n=139	Non-TECSA n=132	TECSA-1 n=7	<i>p</i>
Treatment characteristics					
MAD model	-				0.708
AMO®		61 (43.9%)	58 (43.9%)	3 (42.9%)	
SomnoDent®		11 (7.91%)	10 (7.58%)	1 (14.3%)	
Narval®		1 (0.72%)	1 (0.76%)	0 (0.00%)	
BluePro®		66 (47.5%)	63 (47.7%)	3 (42.9%)	
Nights per week	28	7.00 [6.00; 7.00]	7.00 [6.00; 7.00]	7.00 [5.50; 7.00]	0.589
Hours per night	29	7.00 [6.00; 7.00]	7.00 [6.00; 7.00]	6.00 [5.00; 6.00]	0.071
Effective propulsion (millimeters)	11	7.00 [5.00; 8.00]	7.00 [5.00; 8.00]	7.00 [5.50; 9.00]	0.800
Effective propulsion (/MJAP)	34	0.70 [0.58; 0.80]	0.70 [0.58; 0.80]	0.62 [0.56; 0.71]	0.224

Data are expressed as median [IQR] for quantitative variables, and as numbers and percentages for qualitative variables. The *p*-value corresponds to that obtained using comparison tests (Exact Fisher for qualitative variables, and Mann-Whitney for quantitative variables) between non-TECSA and TECSA-1 patients.

TECSA: treatment-emergent central sleep apnea; MAD: mandibular advancement device; MJAP: maximal active jaw propulsion.

3.3 Clinical outcomes evolution under MAD therapy

The evolution of the three different subjective clinical outcomes (SF-36, QD2A and ESS) between baseline and follow-up in non-TECSA and TECSA-1 patients is shown in *Table V* and *Figures 1 and 2*. Median delta ESS score was equal in both groups (-2 [-6; 1] and -2 [-6; 1], *p*=0.899), however median ESS score at T1 in TECSA-1 group was twice as high as in non-TECSA group (12 [8; 14]/24 in TECSA-1 group vs 6 [3; 9]/24 in non-TECSA group, *p*=0.899). *Figure 1* shows a similar downward trend of ESS in both groups under MAD treatment. However, baseline ESS appears to be higher in TECSA-1 group and remains so at follow-up. The difference between median delta QD2A score in both groups was not statistically significant

(-1 [-2; 0] vs 0 [-2; 2] respectively for non-TECSA and TECSA-1 patients, $p=0.429$). Median delta SF-36 score for the General health scale was significantly lower in TECSA-1 group (-8 [-25; -1] in TECSA-1 group vs 5 [-5; 15] in non-TECSA-group, $p=0.028$). No statistical differences were found in median delta SF-36 for the other seven scales, but a trend towards lower scores for Mental health category was observed in TECSA-1 patients (-2 [-10; 3] in TECSA-1 group vs 4 [-4; 12] in non-TECSA group, $p=0.052$).

Table V. Comparison between T0 and T1 (Epworth Sleepiness Scale, QD2A, SF-36) for non-TECSA and TECSA-1 patients.

Variables	Non-TECSA (n=132)			TECSA-1 (n=7)			<i>p</i>
	T0	T1	Δ T1-T0	T0	T1	Δ T1-T0	
ESS	10 [6; 13]	6 [3; 9]	-2 [-6; 1]	13 [10; 18]	12 [8; 14]	-2 [-6; 1]	0.899
QD2A	1 [0; 4]	0 [0; 2]	-1 [-2; 0]	2 [2; 6]	3 [2; 6]	0 [-2; 2]	0.429
SF-36							
PF	95 [90; 95]	95 [90; 100]	0 [-5; 5]	90 [90; 98]	90 [90; 90]	-3 [-8; 5]	0.492
RP	100 [75; 100]	100 [75; 100]	0 [0; 0]	75 [38; 100]	63 [50; 75]	-13 [-25; 19]	0.470
RE	100 [67; 100]	67 [67; 100]	0 [0; 0]	100 [67; 100]	50 [33; 92]	-17 [-33; 0]	0.179
VT	45 [35; 55]	55 [45; 65]	5 [0; 19]	45 [30; 55]	38 [31; 40]	0 [-5; 9]	0.183
MH	68 [56; 76]	76 [60; 84]	4 [-4; 12]	72 [56; 78]	62 [50; 74]	-2 [-10; 3]	0.052
SF	75 [63; 100]	88 [63; 100]	0 [-13; 25]	75 [63; 81]	63 [53; 81]	-6 [-13; 0]	0.442
BP	70 [58; 80]	80 [68; 80]	0 [0; 13]	80 [63; 80]	68 [58; 77]	-6 [-13; 0]	0.061
GH	65 [51; 79]	70 [60; 84]	5 [-5; 15]	65 [58; 80]	55 [48; 63]	-8 [-25; -1]	0.028

Data are expressed median [IQR], and p -values compare the delta between T0 and T1 of non-TECSA versus TECSA-1 patients using a Mann-Whitney test.

TECSA: treatment-emergent central sleep apnea; ESS: Epworth sleepiness scale; QD2A: self-assessment questionnaire for depressive symptoms; SF-36: 36-Item Short Form Survey; PF: physical functioning; RP: role physical; RE: role emotional; VT: vitality; MH: mental health; SF: social functioning; BP: bodily pain; GH: general health.




Figure 1. Individual ESS scores trajectories during follow-up in non-TECSA and TECSA-1 patients.

TECSA: treatment-emergent central sleep apnea.




Figure 2. Violin plots comparing Delta Epworth Sleepiness Scale distribution in non-TECSA and TECSA-1 patients.

TECSA: treatment-emergent central sleep apnea.

4. DISCUSSION

To our knowledge, this is the largest study to assess the prevalence of TECSA in patients treated with a MAD, and the first to do so on a prospective cohort. We found a prevalence of 5.04%, 1.44% and 0% for TECSA-1, -2 and -3 respectively. This study is also the first to assess the clinical impact of TECSA in patients treated with a MAD. Median delta SF-36 score for the General health scale was significantly lower in TECSA-1 patients and there was a trend towards lower scores for Mental health category in TECSA-1 group. Baseline and follow-up ESS showed a trend towards a higher score in TECSA-1 patients compared to non-TECSA patients, with a high proportion of TECSA-1 patients suffering from EDS before treatment initiation.

According to the 2014 ICSD-3, TECSA is characterized by the persistence or emergence of CSA (which cannot be explained by another disorder) on exposure to CPAP devices without a backup rate while initial obstructive respiratory events have resolved [6]. This new definition clarifies what was previously described as “complex sleep-disordered breathing”, or “complex sleep apnea syndrome” and emphasizes the iatrogenic nature of the phenomenon [21,22]. TECSA has been widely studied in OSAS patients treated with CPAP devices. An overall incidence of 6.5% for CPAP-related TECSA has been reported in the largest study so far [23]. An aggregate point prevalence of 8% with an estimated range varying from 5.0% to 20.3% has been found in a systematic literature review [7]. Although CPAP therapy is specifically mentioned in the ICSD-3 definition of TECSA, a growing number of studies have highlighted the fact that TECSA may also occur with alternative treatment modalities of OSAS such as tracheostomy, hypoglossal nerve stimulation or maxillomandibular advancement surgery [24–26]. To date, the occurrence of TECSA after MAD therapy has been rarely studied [11,27–31].

According to the definition selected, a prevalence between 0% and 5.04% was found in the present study. Despite MAD being the main alternative to CPAP in OSAS treatment, only two retrospective studies assessed the incidence of TECSA in MAD population and the potential risk factors.

Ciavarella et al. assessed the occurrence of TECSA in a cohort of 56 patients treated with a MAD for OSAS. In their study, any patient showing the emergence or persistence of CSA during the follow-up PSG was considered TECSA, without defined CSA threshold. Following this overly broad definition of TECSA, they found that 16 out of 56 patients belonged to what could be called the "TECSA-group", giving a prevalence of 40% for TECSA in this article. This definition was not used in the present work because we consider it is too broad and it is not clinically relevant [31].

Helleman et al. carried out a retrospective study to assess the prevalence of TECSA in a cohort of 129 patients treated with a MAD. The prevalence of TECSA was assessed after a median time interval of 3 months following MAD initiation. The authors proposed three definitions of TECSA that we decided to replicate in our study to standardize results. They found higher TECSA prevalences than in our study (7.8%, 4.7% and 3.1% for TECSA-1, 2 and 3 respectively) [11].

A possible explanation for the low prevalence of MAD-related TECSA compared to the reported prevalence of CPAP-related TECSA could be the delay between the initiation of treatment and the diagnosis of TECSA. While TECSA recorded by CPAP softwares are immediately identified during diagnostic sleep studies, MAD-related TECSA are discovered during a second recording, usually made several months after the initial polysomnography, as in our study. Furthermore,

several studies have shown that TECSA tends to resolve spontaneously in a significant number of cases [23,32]. Liu et al. proposed different trajectories for the natural course of TECSA in a very large CPAP database study including 133 006 patients assessed by PSG at week 1 and week 13. The overall prevalence of TECSA was 3.5% in their study. Among these patients, TECSA was transient in 55.1%, persistent in 25.2%, or emergent in 19.7% [9]. The natural course of TECSA with non-CPAP therapies has not been as well studied yet, mainly because TECSA is not systematically re-assessed in most studies, but cases of spontaneous resolution exist in the literature [30,33]. In our study population, the median time interval between MAD treatment initiation and follow-up sleep recording was 10 months. Therefore, we can assume that the relatively lower prevalence of TECSA observed in our study and more generally in most studies assessing the prevalence of this phenomenon with non-CPAP treatments of OSAS is at least partly due to the spontaneous resolution of some of the cases ("transient-TECSA") with ongoing treatment.

Another reason that could explain the differences observed in literature in terms of TECSA's prevalence may be the lack of comparability between CPAP and MAD populations regarding demographic data, comorbid conditions and polysomnographic parameters. In our study population, MAD treated patients seemed younger, less severely obese, had fewer metabolic and cardiovascular comorbidities and relatively less severe OSAS than patients treated with CPAP in the same cohort [34]. As some of these parameters are described in the literature as potential predictive factors of CPAP-related TECSA, such as high baseline AHI or cardiovascular comorbidities, we can assume that their lower prevalence in patients treated with a MAD partly explains the lower incidence of TECSA in this population [8].

Lastly, the diversity of diagnostic criteria used to define TECSA, as well as the multiplicity of methodologies employed in the literature may contribute to the variability of the results obtained in terms of prevalence [7].

To address this issue and facilitate comparisons between studies, we chose to use the diagnostic criteria defined in the largest MAD related-TECSA study to date [11]. TECSA-1 is the broadest definition of TECSA, shared by most studies. However, this definition does not take into account the resolution of obstructive events and may lead to an overestimation of the phenomenon. TECSA-2 refines the definition of TECSA-1 by taking into consideration the effectiveness of OSAS treatment, defined by a $\geq 50\%$ reduction in OAHl under MAD therapy. TECSA-3 can be compared to “emergent-TECSA” or “truly emergent-CSA”, adding to the two previous definitions a baseline CAHI $< 5/h$ [9,23]. Nevertheless, this definition is probably too restrictive to properly define TECSA and may lead to an underestimation of the phenomenon. In our study, none of the patients fulfilled the diagnostic criteria for TECSA-3.

Many potential risk factors associated with CPAP-related TECSA have been highlighted in the literature, including demographic data (older age, male sex, lower BMI), comorbid conditions (coronary artery disease, hypertension, chronic heart failure, atrial fibrillation, stroke), polysomnographic characteristics (higher baseline AHI, CAI and arousal index, increased CAI in non-REM-sleep) and titration factors (for example excessive titration or air leak, higher residual AHI under CPAP-therapy) [8]. However, little is known about the potential risk factors associated with MAD-related TECSA. Ciavarella et al. did not show any statistical differences between non-TECSA and TECSA patients in their study regarding demographic data, comorbid conditions, polysomnographic parameters or MAD characteristics [31]. Hellemans et al. found that TECSA-2 patients had significantly higher baseline CAHI, AI and 3% ODI than non-TECSA

patients. Still, no statistically significant differences were found regarding demographic data or MAD characteristics. Furthermore, potential association between TECSA and comorbid conditions were not assessed in their study [11]. Our results are in line with these studies. We did not identify any statistically significant risk factors for MAD-related TECSA in our study. No significant differences were found in terms of demographic data and comorbid conditions, although there seemed to be a trend towards a higher prevalence of arterial hypertension in TECSA-1 than in non-TECSA group. Similarly, baseline ESS showed a trend that did not reach statistical significance to a higher score in TECSA-1 patients compared to non-TECSA patients with a high proportion of TECSA-1 patients suffering from EDS before initiation of treatment. No other potential risk factors were found in the study population, especially in terms of MAD characteristics or sleep architecture.

The clinical relevance of TECSA remains controversial [8,10,23]. Even if TECSA appears to resolve spontaneously in most cases, it may also persist and in this case, it seems to be associated with a higher risk of poor adherence and therapy discontinuation [9,23,35]. However, little is known about the impact of TECSA on compliance to MAD therapy. Hellemans et al. noted that of the six TECSA-2 cases in their study population, five were able to continue MAD treatment and only one had residual fatigue and was subsequently successfully treated with CPAP [11]. These results are consistent with ours, with a good adherence to MAD therapy and no statistical differences found in terms of compliance to treatment between TECSA-1 and non-TECSA groups in our study population. We did not find either any statistical differences in our study population regarding delta Pichot's QD2A and delta ESS scores between baseline and follow-up. However, there appeared to be a trend towards higher ESS scores at follow-up in TECSA-1 group compared to non-TECSA patients under treatment. Thus, MAD therapeutic efficacy appeared to be similar between non-TECSA and TECSA-1 patients in the study

population, but as TECSA-1 patients were sleepier at baseline, they remained so at T1. Median delta SF-36 score for the General health scale was significantly lower in TECSA-1 group and there was a trend towards lower scores for Mental health category in TECSA-1 patients. Overall, subjective clinical outcomes appeared to be poorer at follow-up in patients with TECSA under MAD treatment. Thus, symptomatic impact of TECSA remains a central question and may determine the eventual clinical management of this pathology.

Clinical management of TECSA remains controversial. Considering TECSA is a self-limited and transient phenomenon in most cases, some authors suggest a wait-and-see strategy without changing treatment modalities, and an objective reassessment of therapeutic efficacy after several months to allow ventilatory control to self-regulate [8,10,30]. However, it may be difficult not to intervene if patients remain symptomatic or present with severely impaired PSG characteristics under treatment. Such patients should probably be reassessed earlier with a new sleep recording. Increasing or decreasing MAD advancement might be relevant, as inadequate setting of the device could contribute to the pathophysiology of MAD-related TECSA [28,36]. Several other treatment modalities, such as CPAP, adaptative servo-ventilation or acetazolamide might be effective adjuncts, as they showed efficacy or promising results in CPAP-related TECSA, yet no studies have been carried out to recommend their use in MAD-related TECSA [8,10,35,37].

The present study has some limitations. First, it is limited by the relatively small sample size, despite being the largest studied MAD-TECSA population to date. Its prospective design enabled reliable collection of demographic and clinical characteristics of the patients. However, some essential data could not be collected, such as opioid consumption at the time of diagnosis, which may have influenced the results. Due to the low prevalence of TECSA, our statistical

comparisons are based on a small number of patients, which makes it difficult to identify any potential risk factors of this phenomenon. Yet, this is the first study suggesting probably poorer subjective clinical outcomes in terms of sleepiness and quality of life in patients with MAD-related TECSA.

5. CONCLUSIONS

Although it is a rare and mostly transient phenomenon, clinicians should be aware of MAD-related TECSA as it may be associated with poorer clinical results. Systematic follow-up sleep studies and clinical assessments would enable early detection of symptomatic patients whose TECSA does not resolve spontaneously over the time. In such cases, clinicians should consider modifying MAD advancement or use of alternative therapies on an individual basis.

To our knowledge, this study is the first to assess the clinical impact of TECSA in patients treated with a MAD. Further research will be required to assess the potential predictive factors associated with MAD-related TECSA in larger cohorts, to clarify the underlying pathophysiological mechanisms and to determine its possible long-term consequences regarding adherence to treatment and clinical outcomes.

REFERENCES

- [1] Schwartz M, Acosta L, Hung Y-L, Padilla M, Enciso R. Effects of CPAP and mandibular advancement device treatment in obstructive sleep apnea patients: a systematic review and meta-analysis. *Sleep Breath.* 2018;22:555–68. <https://doi.org/10.1007/s11325-017-1590-6>.
- [2] Trzepizur W, Cistulli PA, Glos M, Vielle B, Sutherland K, Wijkstra PJ, et al. Health outcomes of continuous positive airway pressure versus mandibular advancement device for the treatment of severe obstructive sleep apnea: an individual participant data meta-analysis. *Sleep* 2021;44:zsab015. <https://doi.org/10.1093/sleep/zsab015>.
- [3] Sutherland K, Cistulli PA. Oral Appliance Therapy for Obstructive Sleep Apnoea: State of the Art. *J. Clin. Med.* 2019;8:2121. <https://doi.org/10.3390/jcm8122121>.
- [4] Bratton DJ, Gaisl T, Wons AM, Kohler M. CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis. *J. Am. Med. Assoc.* 2015;314:2280. <https://doi.org/10.1001/jama.2015.16303>.
- [5] Bettega G, Breton P, Goudot P, Saint-Pierre F. Place de l'orthèse d'avancée mandibulaire (OAM) dans le traitement du syndrome d'apnées hypopnées obstructives du sommeil de l'adulte (SAHOS). *Juillet 2014. Rev. Stomatol. Chir.* 2015;116:28–57. <https://doi.org/10.1016/j.revsto.2014.12.001>.
- [6] Sateia MJ. International Classification of Sleep Disorders-Third Edition. *Chest* 2014;146:1387–94. <https://doi.org/10.1378/chest.14-0970>.
- [7] Nigam G, Pathak C, Riaz M. A systematic review on prevalence and risk factors associated with treatment-emergent central sleep apnea. *Ann. Thorac. Med.* 2016;11:202. <https://doi.org/10.4103/1817-1737.185761>.
- [8] Zhang J, Wang L, Guo H-J, Wang Y, Cao J, Chen B-Y. Treatment-emergent central sleep apnea: a unique sleep-disordered breathing. *Chin. Med. J.* 2020;133:2721–30. <https://doi.org/10.1097/CM9.0000000000001125>.

- [9] Liu D, Armitstead J, Benjafield A, Shao S, Malhotra A, Cistulli PA, et al. Trajectories of Emergent Central Sleep Apnea During CPAP Therapy. *Chest* 2017;152:751–60. <https://doi.org/10.1016/j.chest.2017.06.010>.
- [10] Berger M, Solelhac G, Horvath C, Heinzer R, Brill A-K. Treatment-emergent central sleep apnea associated with non-positive airway pressure therapies in obstructive sleep apnea patients: A systematic review. *Sleep Med. Rev.* 2021;58:101513. <https://doi.org/10.1016/j.smr.2021.101513>.
- [11] Hellemans S, Van De Perck E, Braem MJ, Verbraecken J, Dieltjens M, Vanderveken OM. The prevalence of treatment-emergent central sleep apnea with mandibular advancement device therapy. *J. Clin. Sleep Med.* 2023:jcs.10742. <https://doi.org/10.5664/jcs.10742>.
- [12] Phillips CL, Grunstein RR, Darendeliler MA, Mihailidou AS, Srinivasan VK, Yee BJ, et al. Health Outcomes of Continuous Positive Airway Pressure versus Oral Appliance Treatment for Obstructive Sleep Apnea: A Randomized Controlled Trial. *Am. J. Respir. Crit. Care Med.* 2013;187:879–87. <https://doi.org/10.1164/rccm.201212-2223OC>.
- [13] Gagnadoux F, Pépin J-L, Vielle B, Bironneau V, Chouet-Girard F, Launois S, et al. Impact of Mandibular Advancement Therapy on Endothelial Function in Severe Obstructive Sleep Apnea. *Am. J. Respir. Crit. Care Med.* 2017;195:1244–52. <https://doi.org/10.1164/rccm.201609-1817OC>.
- [14] Gagnadoux F, Nguyen X-L, Le Vaillant M, Priou P, Meslier N, Eberlein A, et al. Comparison of titrable thermoplastic versus custom-made mandibular advancement device for the treatment of obstructive sleep apnoea. *Respir. Med.* 2017;131:35–42. <https://doi.org/10.1016/j.rmed.2017.08.004>.
- [15] Attali V, Vecchierini M-F, Collet J-M, d'Ortho M-P, Goutorbe F, Kerbrat J-B, et al. Efficacy and tolerability of a custom-made Narval mandibular repositioning device for the treatment of

- obstructive sleep apnea: ORCADES study 2-year follow-up data. *Sleep Med.* 2019;63:64–74. <https://doi.org/10.1016/j.sleep.2019.04.021>.
- [16] Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, et al. Rules for Scoring Respiratory Events in Sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events: Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. *J. Clin. Sleep Med.* 2012;8:597–619. <https://doi.org/10.5664/jcsm.2172>.
- [17] Johns MW. A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale. *Sleep* 1991;14:540–5. <https://doi.org/10.1093/sleep/14.6.540>.
- [18] De Bonis M, Lebeaux MO, De Boeck P, Simon M, Pichot P. Measuring the severity of depression through a self-report inventory. *J. Affect. Disord.* 1991;22:55–64. [https://doi.org/10.1016/0165-0327\(91\)90084-6](https://doi.org/10.1016/0165-0327(91)90084-6).
- [19] Gagnadoux F, Le Vaillant M, Goupil F, Pigeanne T, Chollet S, Masson P, et al. Symptômes dépressifs avant et après traitement prolongé par PPC pour SAHOS. *Rev. Mal. Respir.* 2015;32:A13. <https://doi.org/10.1016/j.rmr.2014.11.037>.
- [20] Ware JE, work(s): CDSR. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection. *Med. Care* 1992;30:473–83. JSTOR, <http://www.jstor.org/stable/3765916>.
- [21] Gilmartin GS, Daly RW, Thomas RJ. Recognition and management of complex sleep-disordered breathing. *Curr. Opin. Pulm. Med.* 11:485-493. <https://doi.org/10.1097/01.mcp.0000183061.98665.b0>
- [22] Morgenthaler TI, Kagramanov V, Hanak V, Decker PA. Complex Sleep Apnea Syndrome: Is It a Unique Clinical Syndrome? *Sleep* 2006;29(9):1203-1209. <https://doi.org/10.1093/sleep/29.9.1203>

- [23] Javaheri S, Smith J, Chung E. The Prevalence and Natural History of Complex Sleep Apnea. *J. Clin. Sleep Med.* 2009;05:205–11. <https://doi.org/10.5664/jcsm.27486>.
- [24] Guilleminault C, Cummiskey J. Progressive improvement of apnea index and ventilatory response to CO₂ after tracheostomy in obstructive sleep apnea syndrome. *Am. Rev. Respir. Dis.* 1982;126:14–20. <https://doi.org/10.1164/arrd.1982.126.1.14>.
- [25] Patel J, Daniels K, Bogdan L, Huntley C, Boon M. Elevated Central and Mixed Apnea Index after Upper Airway Stimulation. *Otolaryngol-Head Neck Surg.* 2020;162:767–72. <https://doi.org/10.1177/0194599820912740>.
- [26] Goodday RH, Fay MB. Emergence of Central Sleep Apnea Events After Maxillomandibular Advancement Surgery for Obstructive Sleep Apnea. *J. Oral Maxillofac. Surg.* 2019;77:2303–7. <https://doi.org/10.1016/j.joms.2019.06.002>.
- [27] Avidan A. The development of central sleep apnea with an oral appliance. *Sleep Med.* 2006;7:85–6. <https://doi.org/10.1016/j.sleep.2005.06.002>.
- [28] Gindre L, Gagnadoux F, Meslier N, Fleury B, Gustin JM, Racineux JL. Apnées centrales induites sous traitement par orthèse d'avancée mandibulaire. *Rev. Mal. Respir.* 2006;23:477–80. [https://doi.org/10.1016/S0761-8425\(06\)71821-6](https://doi.org/10.1016/S0761-8425(06)71821-6).
- [29] Kuźniar TJ, Kovačević-Ristanović R, Freedom T. Complex sleep apnea unmasked by the use of a mandibular advancement device. *Sleep Breath.* 2011;15:249–52. <https://doi.org/10.1007/s11325-010-0459-8>.
- [30] Mohan A, Henderson J, Mador MJ. Mandibular Advancement Device—Emergent Central Sleep Apnea Can Resolve Spontaneously: A Case Report. *J. Clin. Sleep Med.* 2016;12:137–8. <https://doi.org/10.5664/jcsm.5414>.
- [31] Ciavarella D, Ferrara D, Cazzolla AP, Burlon G, Tepedino M. Treatment Emergent Central Sleep Apnea Evaluation in Patients Treated with Mandibular Advancement Device. *Appl. Sci.* 2022;12:12040. <https://doi.org/10.3390/app122312040>.

- [32] Cassel W, Canisius S, Becker HF, Leistner S, Ploch T, Jerrentrup A, et al. A prospective polysomnographic study on the evolution of complex sleep apnoea. *Eur. Respir. J.* 2011;38:329–37. <https://doi.org/10.1183/09031936.00162009>.
- [33] Corcoran S, Mysliwiec V, Niven AS, Fallah D. Development of Central Sleep Apnea After Maxillofacial Surgery for Obstructive Sleep Apnea. *J. Clin. Sleep Med.* 2009;05:151–3. <https://doi.org/10.5664/jcsm.27444>.
- [34] Gervès-Pinquier C, Bailly S, Goupil F, Pigeanne T, Launois S, Leclair-Visonneau L, et al. Positive Airway Pressure Adherence, Mortality, and Cardiovascular Events in Patients with Sleep Apnea. *Am. J. Respir. Crit. Care Med.* 2022;206:1393–404. <https://doi.org/10.1164/rccm.202202-0366OC>.
- [35] Pépin J-LD, Woehrle H, Liu D, Shao S, Armitstead JP, Cistulli PA, et al. Adherence to Positive Airway Therapy After Switching From CPAP to ASV: A Big Data Analysis. *J. Clin. Sleep Med.* 2018;14:57–63. <https://doi.org/10.5664/jcsm.6880>.
- [36] Guilleminault C, Robinson A. Central sleep apnea, upper airway resistance and sleep. *Sleep Med.* 2006;7:189–91. <https://doi.org/10.1016/j.sleep.2005.10.002>.
- [37] Glidewell RN, Orr WC, Imes N. Acetazolamide as an Adjunct to CPAP Treatment: A Case of Complex Sleep Apnea in a Patient on Long-Acting Opioid Therapy. *J. Clin. Sleep Med.* 2009;05:63–4. <https://doi.org/10.5664/jcsm.27394>.

LEGENDS OF FIGURES

Figure 1: Individual ESS scores trajectories during follow-up in non-TECSA and TECSA-1 patients. 15

Figure 2: Violin plots comparing Delta Epworth Sleepiness Scale distribution in non-TECSA and TECSA-1 patients..... 15

TABLES

Table I: Baseline demographics and comorbidities of the study population.....	10
Table II: Baseline sleep recordings data of the study population.....	11
Table III: Subjective clinical outcomes' scores for the study population at baseline.....	12
Table IV: Treatment characteristics of the study population.....	13
Table V: Comparison between T0 and T1 (Epworth Sleepiness Scale, QD2A, SF-36) for non-TECSA and TECSA-1 patients.....	14

TABLE DES MATIÈRES

ABSTRACT	2
INTRODUCTION	4
MATERIALS AND METHODS.....	5
2.1 Study population and design.....	5
2.2 MAD treatment.....	5
2.3 Sleep recordings.....	6
2.4 Subjective clinical outcomes.....	6
2.5 TECSA definitions.....	7
2.6 Statistical analysis.....	7
RESULTS.....	8
3.1 Baseline characteristics of the study population.....	8
3.2 Comparisons between non-TECSA and TECSA patients.....	8
3.3 Clinical outcomes evolution under MAD therapy.....	13
DISCUSSION	16
CONCLUSIONS	22
REFERENCES	23
LEGENDS OF FIGURES.....	28
TABLES.....	29
TABLE DES MATIÈRES	30

Publication :

Ce travail a été soumis le 27/08/2024 sous la forme d'un article original dans la revue internationale à comité de lecture « Sleep Medicine » (Rang SIGAPS : C ; Impact Factor : 3.8).

Apnées centrales du sommeil émergentes sous traitement par orthèse d'avancée mandibulaire

RÉSUMÉ

Objectifs : Les apnées centrales du sommeil émergentes sous traitement (treatment-emergent central sleep apnea, TECSA) sont un phénomène reconnu dans le cadre de la thérapie par pression positive continue. Cependant, elles ont été très peu étudiées dans le cadre du traitement par orthèse d'avancée mandibulaire (OAM). Cette étude vise à évaluer la prévalence des TECSA chez les patients traités par OAM et à déterminer leurs facteurs de risque ainsi que leur impact clinique.

Matériels et méthodes : Un total de 139 patients issus de la cohorte du sommeil de l'IRSR des Pays de la Loire souffrant de ronflements ou d'un syndrome d'apnée obstructive du sommeil (SAOS) et traités par une OAM sur mesure et ajustable ont été inclus dans cette étude. Les enregistrements du sommeil réalisés à l'inclusion et au cours du suivi ont permis d'identifier les patients atteints de TECSA. Des analyses comparatives ont été effectuées entre les groupes TECSA et non-TECSA afin d'identifier les facteurs de risque potentiels. La pertinence clinique des TECSA dans les deux groupes a été évaluée à l'inclusion et lors du suivi par le questionnaire d'auto-évaluation de Pichot pour les symptômes dépressifs (QD2A), le questionnaire de qualité de vie SF-36 et l'échelle de somnolence d'Epworth (ESE).

Résultats : Selon la définition choisie, une prévalence comprise entre 0% et 5.04% a été trouvée pour les TECSA dans cette étude. Aucune différence statistique n'a été mise en évidence en termes de caractéristiques du traitement, d'architecture du sommeil, de données démographiques ou de comorbidités. La prévalence de l'hypertension artérielle avait tendance à être plus importante dans le groupe TECSA-1 par rapport au groupe non-TECSA (42.9% contre 25.4% respectivement, $p=0.379$). L'ESE initial avait tendance à être plus élevé chez les patients TECSA-1 par rapport aux patients non-TECSA (13/24 contre 10/24 respectivement, $p=0.074$), avec une forte proportion de patients TECSA-1 souffrant de somnolence diurne excessive avant l'initiation du traitement (85.7%, contre 52.4% chez les patients non-TECSA, $p=0.124$). Aucune différence statistique n'a été trouvée concernant les deltas des scores QD2A et ESE entre l'inclusion et le suivi, bien que les scores ESE avaient tendance à être plus élevés lors du suivi dans le groupe TECSA-1 par rapport aux patients non-TECSA. Le delta médian pour l'échelle de la santé générale du score SF-36 était significativement plus faible dans le groupe TECSA-1. Il y avait une tendance à des scores plus faibles pour l'échelle de la santé mentale chez les patients TECSA-1.

Conclusions : Les TECSA sont un phénomène rare pouvant survenir chez les patients traités par OAM pour un SAOS ou des ronflements. Les facteurs de risque cliniques, polysomnographiques ainsi que ceux liés au traitement devront être réévalués dans des cohortes plus importantes. Cette étude suggère des résultats cliniques subjectifs moindres en termes de somnolence et de qualité de vie chez les patients atteints de TECSA liées aux OAM.

Mots-clés : Apnées obstructives du sommeil ; Dispositif d'avancement mandibulaire ; Apnées centrales du sommeil ; Apnées centrales du sommeil émergentes sous traitement.

Treatment-emergent central sleep apnea in patients treated with a mandibular advancement device

ABSTRACT

Objectives: Treatment-emergent central sleep apnea (TECSA) is well established in continuous positive airway pressure therapy but was barely studied in mandibular advancement device (MAD) treatment. This study aims to evaluate the prevalence of TECSA in patients treated with a MAD and to determine its risk factors and clinical relevance.

Materials and methods: A total of 139 patients from the IRSR Pays de la Loire Sleep Cohort suffering from snores or obstructive sleep apnea syndrome (OSAS) and treated with a custom-made titratable MAD were included. Baseline and follow-up sleep recordings enabled identification of TECSA patients. Comparative analyses were carried out between TECSA and non-TECSA groups to identify potential risk factors. Clinical relevance of TECSA in both groups was assessed through baseline and follow-up Pichot's self-assessment questionnaire for depressive symptoms (QD2A), 36-item short form survey (SF-36) and Epworth Sleepiness Scale (ESS) scores.

Results: According to the definition selected, a prevalence between 0% and 5.04% was found for TECSA in the present study. No statistical differences were found in terms of treatment characteristics, sleep architecture, demographic data or comorbid conditions, although there was a trend towards a higher prevalence of arterial hypertension in TECSA-1 than in non-TECSA group (42.9% vs 25.4% respectively, $p=0.379$). Baseline ESS showed a trend towards a higher score in TECSA-1 patients compared to non-TECSA patients (13/24 vs 10/24 respectively, $p=0.074$), with a high proportion of TECSA-1 patients suffering from excessive daytime sleepiness before initiation of treatment (85.7%, vs 52.4% in non-TECSA patients, $p=0.124$). No statistical differences were found regarding delta Pichot's QD2A and ESS scores between baseline and follow-up although there was a trend towards higher ESS scores at follow-up in TECSA-1 group compared to non-TECSA patients. Median delta SF-36 score for the General health scale was significantly lower in TECSA-1 and there was a trend towards lower scores for Mental health category in TECSA-1 patients.

Conclusions: TECSA is a rare phenomenon that can occur in patients treated with a MAD for an OSAS. Clinical, polysomnographic and treatment-related risk factors have yet to be reassessed in larger cohorts. These findings suggest probably poorer subjective clinical outcomes in terms of sleepiness and quality of life in patients with MAD-related TECSA.

Keywords: Obstructive sleep apnea; Mandibular advancement device; Central sleep apnea; Treatment-emergent central sleep apnea.